An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)

Background: Apatinib has been proved to be effective and well tolerated among patients in phase II and III studies. Here, we evaluated the safety and effectiveness of apatinib in advanced gastric cancer patients in a real-world setting. Methods: This study enrolled advanced gastric cancer patients w...

Full description

Bibliographic Details
Main Authors: Xiang Wang, Ruixing Zhang, Nan Du, Mudan Yang, Aimin Zang, Likun Liu, Junyan Yu, Jinghua Gao, Junping Zhang, Zhanzhao Fu, Yuchuan Ren, Liwen Ma, Jun Guo, Qingshan Li, Xiaomei Li, Zaiwen Fan, Xiang Song, Zheng Liu, Yan Zhang, Guozhong Li, Zhonghe Yu, Jianfeng Diao, Junmei Jia, Feng Liang, Huaqing Wang, Junzhong Sun, Yunge Gao, Ping Yang, Chunmei Bai, Xiubao Ren, Diansheng Zhong
Format: Article
Language:English
Published: SAGE Publishing 2020-03-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920905424

Internet

https://doi.org/10.1177/1758835920905424

Similar Items